Cannara Biotech Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Cannara Biotech hat ein Gesamteigenkapital von CA$79.3M und eine Gesamtverschuldung von CA$48.7M, wodurch sich der Verschuldungsgrad auf 61.4% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CA$145.8M bzw. CA$66.5M. Cannara Biotech Das EBIT des Unternehmens beträgt CA$11.5M, so dass der Zinsdeckungsgrad 2.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CA$3.1M.

Wichtige Informationen

61.4%

Verhältnis von Schulden zu Eigenkapital

CA$48.68m

Verschuldung

Zinsdeckungsgrad	2.5x
Bargeld	CA$3.13m
Eigenkapital	CA$79.34m
Gesamtverbindlichkeiten	CA$66.48m
Gesamtvermögen	CA$145.82m

Jüngste Berichte zur Finanzlage

Recent updates

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

May 09

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Jan 24

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Dec 18

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Jul 29

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: LOVEDie kurzfristigen Aktiva des Unternehmens (CA$58.2M) decken seine kurzfristigen Passiva (CA$60.1M) nicht.

Langfristige Verbindlichkeiten: LOVEDie kurzfristigen Vermögenswerte des Unternehmens (CA$58.2M) übersteigen seine langfristigen Verbindlichkeiten (CA$6.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: LOVEDie Nettoverschuldung im Verhältnis zum Eigenkapital (57.4%) wird als hoch angesehen.

Schulden abbauen: LOVEDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 38.9% auf 61.4% gestiegen.

Schuldendeckung: LOVEDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (16.6%) gedeckt.

Zinsdeckung: LOVEDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (2.5x Deckung) nicht gut gedeckt.

Cannara Biotech Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Recent updates

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

Second quarter 2024 earnings released: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023)

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023)

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022)

Insufficient new directors

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022)

Independent Director recently bought CA$60k worth of stock

Investor sentiment improves as stock rises 24%

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022)

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022)

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023

Independent Director recently bought CA$117k worth of stock

Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021)

Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro Ark

Independent Director recently bought CA$81k worth of stock

Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021)

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Cannara Biotech Inc. Announces New Products Launch

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cannara Biotech Inc. Receives Processing and Cultivation License

Cannara Biotech Inc. Receives Amendment of Its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of Its Hash Product Line in Quebec

Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020)

Cannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc.

Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million.

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020)

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Full year 2020 earnings released: CA$0.017 loss per share

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021

Cannara Biotech Inc. Appoints Donald Olds to Board of Directors

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen